May 14, 2015, 00:00
by
Michael Croft
May 14, 2015 | Amid accusations the drug maker
misled investors and patients about the safety of its drug,
Orexigen Therapeutics is now feuding with Takeda Pharmaceutical,
its marketing partner, over the cost of a clinical trial that was
required by the FDA. WSJ